Reminder: Monthly Meeting of SB Club this September 30, 2024
- Post by: Ahmad Saleh
- September 26, 2024
- No Comment
(Please, ignore this if you already registered for this activity).
We would like to inform you that the monthly online meeting of Synthetic Biology Club (SB club) will be held this Monday, September 30, 2024 at 12h00 (EST). Please, Click here to register after which you will receive the meeting link (zoom).
Title: “Golden Gate Assembly Systems for the Rapid Engineering of Bacteriophage Genomes”
Presenter: Gregory Lohman, Research professional at New England Biolabs Research Department Applied Molecular Biology Division 240 County Rd. Ipswich, MA 01938
Time: Monday, September 30, 2024 at 12h00 (EST).
Place: Online (via Zoom). The zoom link of the meeting is provided by email after your registration. Click here to register.
Abstract: Data-optimized Assembly Design applies comprehensive measurements of ligation fidelity to flexibly select high-fidelity sets of fusion sites for Golden Gate Assembly (GGA), permitting accurate and efficient assembly of dozens of parts in a single reaction and reliable assembly of small genomes up to 50 kb in a single assembly round. Using this approach we have developed modular, one-step assembly of Escherichia coli phages T7 and Lambda, Pseudomonas aeruginosa phage ɸKMV, and Mycobacterium smegmatis phage BPs,. Small (<5 kB), plasmid-propagatable parts support mutagenesis via classic molecular biology methods and allow inexpensive whole gene swaps by substitution of new parts. All systems are rescued directly by transformation into the appropriate host with a near 100% success rate for the introduction of desired mutations and <1 unintended mutation per ~100 kb when fragments are generated by PCR and <1 in 500 kb when parts are sequence validated clones in plasmids. These systems are being applied to study biology, including replication behavior and host range. The ɸKMV and BPs systems further represent model engineering systems for the development of phage therapeutics targeting multidrug-resistant human pathogens.